Mass spectrometry (MS)-based immunopeptidomics is an attractive antigen discovery method with growing clinical implications. However, the current experimental approach to extract HLA-restricted peptides requires a bulky sample source, which remains a challenge for obtaining clinical specimens. We present an innovative workflow that requires a low sample volume, which streamlines the immunoaffinity purification (IP) and C18 peptide cleanup on a single microfluidics platform with automated liquid handling and minimal sample transfers, resulting in higher assay sensitivity. We also demonstrate how the state-of-the-art data-independent acquisition (DIA) method further enhances the depth of tandem MS spectra-based peptide sequencing. Consequently, over 4,000 and 5,000 HLA-I-restricted peptides were identified from as few as 0.2 million RA957 cells and a melanoma tissue of merely 5 mg, respectively. We also identified multiple immunogenic tumor-associated antigens and hundreds of peptides derived from non-canonical protein sources. This workflow represents a powerful tool for identifying the immunopeptidome of sparse samples.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326370PMC
http://dx.doi.org/10.1016/j.crmeth.2023.100479DOI Listing

Publication Analysis

Top Keywords

ms-based immunopeptidomics
8
microfluidics-enabled automated
4
automated workflow
4
sample
4
workflow sample
4
sample preparation
4
preparation ms-based
4
immunopeptidomics mass
4
mass spectrometry
4
spectrometry ms-based
4

Similar Publications

ProtPipe: A Multifunctional Data Analysis Pipeline for Proteomics and Peptidomics.

Genomics Proteomics Bioinformatics

November 2024

Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.

Article Synopsis
  • Mass spectrometry (MS) is a key technique used for identifying and understanding proteins, which is important for fields like personalized medicine and systems biology.
  • The development of ProtPipe aims to simplify MS data analysis by automating processes like data quality control, sample filtering, and normalization, making it easier to handle complex datasets.
  • ProtPipe also offers various downstream analyses, such as identifying differences in protein abundance and visualizing interactions, and is available as an open-source tool with a user-friendly interface at https://github.com/NIH-CARD/ProtPipe.
View Article and Find Full Text PDF

Advancements in mass spectrometry-based proteomics: a new era in pathology research and diagnostics.

Pathologie (Heidelb)

November 2024

Institut für klinische Pathologie, Universitätsklinikum Freiburg, Breisacher Straße 115a, 79106, Freiburg im Breisgau, Germany.

Background: Mass spectrometry (MS)-based proteomics is rapidly transforming pathology research and diagnostics by enabling comprehensive studies of protein expression and post-translational modifications (PTMs).

Objective: This article discusses recent advancements in MS-based proteomics, focusing on emerging technologies in sample preparation, MS instrumentation, and data analysis. These developments are scrutinized for their applications in clinical cohort studies and molecular pathology diagnostics.

View Article and Find Full Text PDF

Long-range alternative splicing contributes to neoantigen specificity in glioblastoma.

Brief Bioinform

September 2024

State Key Laboratory of Protein and Plant Gene Research, Laboratory of Bioinformatics and Genomic Medicine, Institute of Molecular Medicine, College of Future Technology, Peking University, No. 5 Yiheyuan Road, Haidian District, Beijing 100871, China.

Article Synopsis
  • * Despite a focus on known alternatively-spliced transcripts, non-annotated linear transcripts linked to circular RNAs (circRNAs) remain underexplored, which may have significant implications for cancer treatment.
  • * The study identified 1057 unique long-range alternatively-spliced transcripts in GBM tissues, suggesting they may serve as potential immunotherapy targets due to their specific immunogenic properties.
View Article and Find Full Text PDF

MicroEpitope: an atlas of immune epitopes derived from cancer microbiomes.

Nucleic Acids Res

January 2025

College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang Province 150081, China.

Article Synopsis
  • Scientists found that tiny germs called microbiota inside tumors can affect how our immune system fights cancer.
  • They created a tool called MicroEpitope that collects and studies information about these germ proteins in 24 types of cancer.
  • This tool helps researchers learn more about how these proteins work and could lead to better ways to treat cancer.
View Article and Find Full Text PDF

optiPRM: A Targeted Immunopeptidomics LC-MS Workflow With Ultra-High Sensitivity for the Detection of Mutation-Derived Tumor Neoepitopes From Limited Input Material.

Mol Cell Proteomics

September 2024

Division of Immunotherapy and Immunoprevention, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany; Molecular Vaccine Design, German Center for Infection Research (DZIF), Partner Site Heidelberg, Heidelberg, Germany. Electronic address:

Personalized cancer immunotherapies such as therapeutic vaccines and adoptive transfer of T cell receptor-transgenic T cells rely on the presentation of tumor-specific peptides by human leukocyte antigen class I molecules to cytotoxic T cells. Such neoepitopes can for example arise from somatic mutations and their identification is crucial for the rational design of new therapeutic interventions. Liquid chromatography mass spectrometry (LC-MS)-based immunopeptidomics is the only method to directly prove actual peptide presentation and we have developed a parameter optimization workflow to tune targeted assays for maximum detection sensitivity on a per peptide basis, termed optiPRM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!